162 related articles for article (PubMed ID: 11711531)
1. A nuclear antagonistic mechanism of inhibitory Smads in transforming growth factor-beta signaling.
Bai S; Cao X
J Biol Chem; 2002 Feb; 277(6):4176-82. PubMed ID: 11711531
[TBL] [Abstract][Full Text] [Related]
2. The N domain of Smad7 is essential for specific inhibition of transforming growth factor-beta signaling.
Hanyu A; Ishidou Y; Ebisawa T; Shimanuki T; Imamura T; Miyazono K
J Cell Biol; 2001 Dec; 155(6):1017-27. PubMed ID: 11739411
[TBL] [Abstract][Full Text] [Related]
3. Roles for the MH2 domain of Smad7 in the specific inhibition of transforming growth factor-beta superfamily signaling.
Mochizuki T; Miyazaki H; Hara T; Furuya T; Imamura T; Watabe T; Miyazono K
J Biol Chem; 2004 Jul; 279(30):31568-74. PubMed ID: 15148321
[TBL] [Abstract][Full Text] [Related]
4. Smad6 recruits transcription corepressor CtBP to repress bone morphogenetic protein-induced transcription.
Lin X; Liang YY; Sun B; Liang M; Shi Y; Brunicardi FC; Shi Y; Feng XH
Mol Cell Biol; 2003 Dec; 23(24):9081-93. PubMed ID: 14645520
[TBL] [Abstract][Full Text] [Related]
5. Regulation of transforming growth factor-beta signaling by protein inhibitor of activated STAT, PIASy through Smad3.
Imoto S; Sugiyama K; Muromoto R; Sato N; Yamamoto T; Matsuda T
J Biol Chem; 2003 Sep; 278(36):34253-8. PubMed ID: 12815042
[TBL] [Abstract][Full Text] [Related]
6. Smad6 as a transcriptional corepressor.
Bai S; Shi X; Yang X; Cao X
J Biol Chem; 2000 Mar; 275(12):8267-70. PubMed ID: 10722652
[TBL] [Abstract][Full Text] [Related]
7. Structure-function relationship of inhibitory Smads: Structural flexibility contributes to functional divergence.
Hariharan R; Pillai MR
Proteins; 2008 Jun; 71(4):1853-62. PubMed ID: 18175316
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory smads and tgf-Beta signaling in glomerular cells.
Schiffer M; Schiffer LE; Gupta A; Shaw AS; Roberts IS; Mundel P; Böttinger EP
J Am Soc Nephrol; 2002 Nov; 13(11):2657-66. PubMed ID: 12397035
[TBL] [Abstract][Full Text] [Related]
9. Dissection of inhibitory Smad proteins: both N- and C-terminal domains are necessary for full activities of Xenopus Smad6 and Smad7.
Nakayama T; Berg LK; Christian JL
Mech Dev; 2001 Feb; 100(2):251-62. PubMed ID: 11165482
[TBL] [Abstract][Full Text] [Related]
10. Degradation of the tumor suppressor Smad4 by WW and HECT domain ubiquitin ligases.
Morén A; Imamura T; Miyazono K; Heldin CH; Moustakas A
J Biol Chem; 2005 Jun; 280(23):22115-23. PubMed ID: 15817471
[TBL] [Abstract][Full Text] [Related]
11. Expressions of inhibitory Smads, Smad6 and Smad7, are differentially regulated by TPA in human lung fibroblast cells.
Tsunobuchi H; Ishisaki A; Imamura T
Biochem Biophys Res Commun; 2004 Apr; 316(3):712-9. PubMed ID: 15033458
[TBL] [Abstract][Full Text] [Related]
12. Promoting bone morphogenetic protein signaling through negative regulation of inhibitory Smads.
Itoh F; Asao H; Sugamura K; Heldin CH; ten Dijke P; Itoh S
EMBO J; 2001 Aug; 20(15):4132-42. PubMed ID: 11483516
[TBL] [Abstract][Full Text] [Related]
13. Bone morphogenetic protein and transforming growth factor beta inhibitory Smads 6 and 7 are expressed in human adult normal and osteoarthritic cartilage in vivo and are differentially regulated in vitro by interleukin-1beta.
Kaiser M; Haag J; Söder S; Bau B; Aigner T
Arthritis Rheum; 2004 Nov; 50(11):3535-40. PubMed ID: 15529348
[TBL] [Abstract][Full Text] [Related]
14. Crk-associated substrate lymphocyte type regulates transforming growth factor-beta signaling by inhibiting Smad6 and Smad7.
Inamoto S; Iwata S; Inamoto T; Nomura S; Sasaki T; Urasaki Y; Hosono O; Kawasaki H; Tanaka H; Dang NH; Morimoto C
Oncogene; 2007 Feb; 26(6):893-904. PubMed ID: 16909115
[TBL] [Abstract][Full Text] [Related]
15. Transforming growth factor beta1 induces nuclear export of inhibitory Smad7.
Itóh S; Landström M; Hermansson A; Itoh F; Heldin CH; Heldin NE; ten Dijke P
J Biol Chem; 1998 Oct; 273(44):29195-201. PubMed ID: 9786930
[TBL] [Abstract][Full Text] [Related]
16. NEDD4-2 (neural precursor cell expressed, developmentally down-regulated 4-2) negatively regulates TGF-beta (transforming growth factor-beta) signalling by inducing ubiquitin-mediated degradation of Smad2 and TGF-beta type I receptor.
Kuratomi G; Komuro A; Goto K; Shinozaki M; Miyazawa K; Miyazono K; Imamura T
Biochem J; 2005 Mar; 386(Pt 3):461-70. PubMed ID: 15496141
[TBL] [Abstract][Full Text] [Related]
17. c-Ski acts as a transcriptional co-repressor in transforming growth factor-beta signaling through interaction with smads.
Akiyoshi S; Inoue H; Hanai J; Kusanagi K; Nemoto N; Miyazono K; Kawabata M
J Biol Chem; 1999 Dec; 274(49):35269-77. PubMed ID: 10575014
[TBL] [Abstract][Full Text] [Related]
18. A new partner for inhibitory Smads.
Miyazono K
Cytokine Growth Factor Rev; 2002 Feb; 13(1):7-9. PubMed ID: 11750875
[No Abstract] [Full Text] [Related]
19. Smad7 but not Smad6 cooperates with oncogenic ras to cause malignant conversion in a mouse model for squamous cell carcinoma.
Liu X; Lee J; Cooley M; Bhogte E; Hartley S; Glick A
Cancer Res; 2003 Nov; 63(22):7760-8. PubMed ID: 14633701
[TBL] [Abstract][Full Text] [Related]
20. The balance between acetylation and deacetylation controls Smad7 stability.
Simonsson M; Heldin CH; Ericsson J; Grönroos E
J Biol Chem; 2005 Jun; 280(23):21797-803. PubMed ID: 15831498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
